Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Johnson & Johnson
IndexDJIA S&P500 P/E16.64 EPS (ttm)6.03 Insider Own0.02% Shs Outstand2.82B Perf Week3.45%
Market Cap283.04B Forward P/E16.16 EPS next Y6.21 Insider Trans-0.35% Shs Float2.82B Perf Month-6.97%
Income17.32B PEG2.54 EPS next Q1.26 Inst Own67.10% Short Float0.86% Perf Quarter-1.12%
Sales74.43B P/S3.80 EPS this Y24.60% Inst Trans-0.21% Short Ratio3.42 Perf Half Y1.52%
Book/sh27.25 P/B3.68 EPS next Y4.18% ROA13.10% Target Price107.60 Perf Year13.15%
Cash/sh11.21 P/C8.95 EPS next 5Y6.55% ROE23.20% 52W Range84.31 - 108.77 Perf YTD11.88%
Dividend2.80 P/FCF- EPS past 5Y1.00% ROI15.00% 52W High-7.73% Beta0.61
Dividend %2.79% Quick Ratio2.10 Sales past 5Y2.30% Gross Margin69.30% 52W Low19.04% ATR1.88
Employees126000 Current Ratio2.50 Sales Q/Q5.10% Oper. Margin31.30% RSI (14)44.24 Volatility1.84% 1.85%
OptionableYes Debt/Eq0.22 EPS Q/Q61.20% Profit Margin23.30% Rel Volume1.03 Prev Close99.20
ShortableYes LT Debt/Eq0.17 EarningsOct 14 BMO Payout44.50% Avg Volume7.10M Price100.36
Recom2.50 SMA20-2.62% SMA50-2.97% SMA2001.85% Volume7,284,157 Change1.17%
16-Jul-14Reiterated Deutsche Bank Hold $102 → $107
17-Apr-14Reiterated Argus Buy $104 → $116
16-Apr-14Reiterated RBC Capital Mkts Outperform $104 → $106
10-Jan-14Downgrade Barclays Overweight → Equal Weight $99
07-Jan-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
16-Dec-13Reiterated Deutsche Bank Hold $93 → $95
18-Jul-13Reiterated Argus Buy $96 → $104
17-Jul-13Reiterated Barclays Overweight $95 → $99
17-Jul-13Downgrade Deutsche Bank Buy → Hold $92 → $93
18-Apr-13Reiterated Argus Buy $80 → $96
15-Apr-13Reiterated Barclays Overweight $85 → $95
12-Apr-13Reiterated Deutsche Bank Buy $82 → $87
26-Mar-13Reiterated UBS Buy $81 → $87
11-Jan-13Reiterated UBS Buy $76 → $78
04-Jan-13Upgrade Deutsche Bank Hold → Buy $75 → $82
20-Nov-12Initiated Stifel Nicolaus Hold
18-Jul-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
18-Apr-12Reiterated UBS Buy $71 → $70
12-Dec-11Reiterated UBS Buy $72 → $69
17-Oct-11Reiterated UBS Buy $74 → $72
22-Oct-14 07:45AM  Why Johnson & Johnson (JNJ) Stock Is Higher Today at TheStreet
07:42AM  J&J to spend up to $200M on Ebola vaccine program AP
07:17AM  Consumer inflation report; Stocks look to continue rally; Tesla loses in Michigan Hot Stock Minute
06:51AM  [video] J&J Preps Experimental Ebola Vaccine for May Trial at Bloomberg
06:11AM  J&J, GSK ready to collaborate on Ebola vaccine work Reuters
03:02AM  J&J Says 250,000 Ebola Vaccine Doses to Be Ready by May at Bloomberg
02:19AM  J&J and Bavarian Nordic expand production of an Ebola vaccine program Reuters
02:02AM  Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production PR Newswire
01:55AM  [$$] Johnson & Johnson to Begin Testing Ebola Vaccine in January at The Wall Street Journal
21-Oct-14 07:16PM  Jury deliberations begin in first trial over DePuy's Pinnacle hips Reuters
02:04PM  J&J Ignored Reports Pinnacle Hip Implants Failed: Lawyer at Bloomberg
01:31PM  Vaccines, Medical Oxygen, and Helping the Ebola Crisis Accesswire
11:35AM  Tens of thousands expected to get Ebola vaccines from January - WHO Reuters
11:32AM  Video: Celgene Reports More Good Crohn's Drug Data at Investor's Business Daily
11:32AM  Celgene Reports More Good Crohn's Disease Data Investor's Business Daily
20-Oct-14 09:48PM  Ebola Vaccine Trials Carry Risks for Companies in Chase Bloomberg
09:30PM  Ebola Vaccine Trials Carry Risks for Companies in Chase at Bloomberg
11:16AM  Celgene's Crohn's Disease Drug Hits Its Marks at Investor's Business Daily
11:05AM  EU offers benefits of "orphan" disease status to Ebola drugs Reuters
17-Oct-14 05:15PM  Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy Zacks
02:48PM  Surviving Wall Street's wild ride CNBC
02:48PM  [video] Surviving Wall Street's wild ride at CNBC
12:52PM  [$$] Covidien Wins Patent Injunction Against J&J at The Wall Street Journal
11:00AM  [video] Wild ride for widely-held stocks at CNBC
08:00AM  Signs of stability? Check out widely-held stocks CNBC
08:00AM  [video] Signs of stability? Check out widely-held stocks at CNBC
16-Oct-14 03:56PM  Better Late Than Never? Congress, Courts May Address Limits On Disseminating 'Off Label' Medical Information at Forbes
12:52PM  Bull market over for now: Day trader CNBC
10:38AM  Story Stocks from Briefing.com Briefing.com
08:00AM  Apple's stock is as popular as its iPhones at CNBC
07:45AM  Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2014 PR Newswire
07:44AM  Babsons Noreen, A&Gs Kramer Discuss Global Selloff (Audio) at Bloomberg
15-Oct-14 05:39PM  Was Celgene's Crohn's Disease Drug Worth The Price? at Investor's Business Daily
04:42PM  Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark' Benzinga
03:40PM  Fear rises in stock market as Dow drops 400 points AP
03:39PM  Taking Stock: Babsons Noreen, A&Gs Kramer on Market Selloff at Bloomberg
12:00PM  Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Higher at TheStreet
11:08AM  Stocks off lows but still down on Europe; Financials hit at CNBC
10:53AM  Why Johnson & Johnson (JNJ) Stock Is Up Today at TheStreet
09:52AM  ICAP's Jerry Senser Thinks Boeing And Comcast Look Like Buys In A Beat-Up Market at Forbes
09:41AM  Stock Market News for October 15, 2014 Zacks
07:52AM  UPDATE: Bank Of America Reiterates On Johnson & Johnson On Likely EPS Headwinds Benzinga
12:42AM  [$$] J&Js Earnings Jump on Higher Drug Sales at The Wall Street Journal
12:04AM  Asia stocks rise as oil slump promises benefits AP
14-Oct-14 07:34PM  Johnson & Johnson Raises 2014 Earnings Forecast Again at New York Times
06:00PM  Cramer's investable bottom markers CNBC
05:23PM  [$$] J&J Profit Jumps on Higher Drug Sales at The Wall Street Journal
04:39PM  [video] The Top Ten Stocks for Oct. 14 at Bloomberg
04:20PM  Bristol-Myers Collaborates for Opdivo-Imbruvica Combo Zacks
03:39PM  Money managers worry CNBC
03:32PM  Oil tumbles: When to worry CNBC
03:21PM  Johnson & Johnson Conference Call Highlights Benzinga
01:39PM  J&J slips despite upbeat forecasts at Financial Times
12:30PM  Jim Cramer: 'Do Not Trust This Market' -- It's Irrational Now at TheStreet
12:18PM  J&J hikes 2014 forecast for a third time AP
11:54AM  J&J Earnings Beat; Olysio Chatter Hits Gilead at Investor's Business Daily
11:50AM  JOHNSON & JOHNSON (JNJ) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
11:00AM  Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Lower at TheStreet
10:42AM  Stocks Up, Whittle Early Gains; Skyworks Spikes On Guidance at Investor's Business Daily
10:27AM  J&J Beats Q3 Earnings on Strong Drug Sales, Ups View Zacks
10:26AM  How Will Johnson & Johnson (JNJ) Stock React Today to Its Third Quarter Earnings Results? at TheStreet
10:00AM  Led by Drug Sales, J&J Posts Solid Third Quarter Morningstar
09:59AM  [audio] Newscast: Google launches same-day delivery at MarketWatch
09:40AM  JPM Posts Mixed 3Q as Trading Rebounds, Mortgages Slide at Fox Business
09:23AM  All the reasons to sell this market are enough to draw a guy in at MarketWatch
09:16AM  US STOCKS-Wall St to open higher after 3-day slump, earnings Reuters
09:05AM  Drug Sales Energize Johnson & Johnson Earnings 24/7 Wall St.
09:04AM  Big bank earnings mixed; Johnson & Johnson tops estimates; Costco to enter Chinese market Hot Stock Minute
09:02AM  Cramer: Citi is best CNBC
09:02AM  [video] Cramer: Citi is best at CNBC
08:48AM  US STOCKS-Futures higher after 3-day drop, earnings Reuters
08:34AM  J&J beats Street 3Q forecasts AP
08:22AM  JOHNSON & JOHNSON Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
08:13AM  Johnson & Johnson Quarterly Profit Rises on Sale of Unit at Bloomberg
07:59AM  Johnson & Johnson shares gain after profit beat, raised outlook at MarketWatch
07:55AM  J&J sales top forecast, helped by drug for hepatitis C Reuters
07:53AM  Wall Street watches bank earnings; Google challenges Amazon, McDonald's calls on a Myth Buster Hot Stock Minute
07:45AM  Johnson & Johnson Reports 2014 Third-Quarter Results: PR Newswire
07:28AM  US STOCKS-Futures little changed after 3-day drop; earnings due Reuters
07:07AM  Q3 2014 Johnson & Johnson Earnings Release - Before Market Open CCBN
05:42AM  US bonds jump on market jitters at CNBC
05:35AM  Can banks, tech earnings halt Wall Street's carnage? at CNBC
05:13AM  Premarkets: 4 things to know before the open at CNNMoney.com
13-Oct-14 06:14PM  US STOCKS-Wall St drops in late selloff; worst 3 days for S&P 500 since 2011 Reuters
06:07PM  Can banks, tech earnings halt Wall Street's carnage? at CNBC
05:00PM  US STOCKS-Wall St drops in late selloff; energy, airlines fall Reuters
02:23PM  US STOCKS-Wall St little changed after S&P 500 breaks support Reuters
01:30PM  US STOCKS-Wall St near flat after S&P 500 breaks support Reuters
11:50AM  Will Johnson & Johnson Beat Earnings on Pharma Sales? Zacks
08:30AM  Alios BioPharma Presented Positive Results of Its Anti-RSV Nucleoside Analog AL-8176 in a Phase 2 Challenge Study in Adults Infected With Respiratory Syncytial Virus (RSV) at IDWeek Marketwired
12-Oct-14 07:48AM  Fortune 500 companies spend more than $15bn on corporate responsibility at Financial Times
10-Oct-14 05:30PM  Week Ahead: 3Q Earnings, Retail Sales and Housing at Fox Business
04:46PM  Gilead's Hep C Combo Pill Harvoni Approved, Priced at Investor's Business Daily
04:02PM  Week Ahead: Bank earnings & an Apple announcement CNBC
04:02PM  [video] Week Ahead: Bank earnings & an Apple announcement at CNBC
03:25PM  What to expect from Johnson & Johnsons earnings at MarketWatch
01:52PM  Gilead Wins U.S. Approval for Hepatitis C Combo Pill at Bloomberg
10:42AM  Mali health workers get experimental GSK vaccine in Ebola trials Reuters
09:40AM  Why Johnson & Johnson (JNJ) Stock Is Climbing Today at TheStreet
06:31AM  Should You Buy Johnson & Johnson (JNJ) Ahead of Earnings? Zacks
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women's health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON'S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM
Fasolo PeterVP, Global Human ResourcesMar 14Sale93.156,824635,64015,647Mar 17 06:10 PM
Fasolo PeterVP, Global Human ResourcesMar 04Option Exercise62.6644,8612,811,19243,571Mar 05 06:18 PM
Ullmann Michael HVP, General CounselJan 10Option Exercise0.009,265065,448Jan 14 06:15 PM
Stoffels PaulusChief Scientific OfficerJan 10Option Exercise0.0018,690035,603Jan 14 06:03 PM
Gorsky AlexChairman, CEOJan 10Option Exercise0.0012,058081,579Jan 14 06:01 PM
Fasolo PeterVP, Worldwide Human ResourcesJan 10Option Exercise0.002,58809,310Jan 14 06:00 PM
COSGROVE STEPHEN JCorporate ControllerJan 10Option Exercise0.002,645090,804Jan 14 05:58 PM
Caruso Dominic JVP, Finance; CFOJan 10Option Exercise0.0012,121065,656Jan 14 05:56 PM
Ullmann Michael HVP, General CounselDec 13Option Exercise53.931,85099,77157,277Dec 16 06:18 PM
Fasolo PeterVP, Worldwide Human ResourcesNov 01Option Exercise0.008,620010,595Nov 05 10:58 AM